Medicine Atlas

How Healing Is Practiced
Sign In
Text size
100%
Theme
Condition

Central Retinal Artery Occlusion

Diseases of the Eye and Adnexa

Central retinal artery occlusion is a disease of the eye in which blood flow through the central retinal artery becomes blocked, most commonly by atherosclerosis of the carotid artery, and it typically causes sudden, painless loss of vision in one eye. It occurs at an incidence of roughly 1 in 100,000 people, with risk factors including age over 50, male sex, smoking, hypertension, and diabetes, and irreversible neural damage can begin within about 15 minutes of complete blockage, though this varies among individuals. Diagnosis involves fluorescein angiography and optical coherence tomography.

Facts
Classification
Body System
Cardiovascular System 1
ICD-10 Chapter
VII: Diseases of the Eye and Adnexa 2
Communicable or Non-communicable
Non-Communicable 3
Transmission Route
Non-Transmissible 3
Sources
1. Wikipedia: Central retinal artery occlusion
WikipediaLead section, body-system statement
Quote, Lead section, body-system statement
Central retinal artery occlusion (CRAO) is a disease of the eye where the flow of blood through the central retinal artery is blocked (occluded).
View the Source
2. Wikipedia: ICD-10
WikipediaList of chapters, Chapter VII
Quote, List of chapters, Chapter VII
Diseases of the eye and adnexa
View the Source
3. Wikipedia: Non-communicable disease
Wikipedia
  • Lead section, transmission-route statement (inferred from disease-category)
    NCDs include Parkinson's disease, autoimmune diseases, strokes, heart diseases, cancers, diabetes, chronic kidney disease, osteoarthritis, osteoporosis, Alzheimer's disease, cataracts, and others.
  • Named examples section
    NCDs include Parkinson's disease, autoimmune diseases, strokes, heart diseases, cancers, diabetes, chronic kidney disease, osteoarthritis, osteoporosis, Alzheimer's disease, cataracts, and others.
View the Source
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.